Weeks 20 through 48 (maintenance): check-ins every 8 to 12 weeks
Analysis of nearly 8,000 adults found 45% keep the weight off after one year As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings
Conclusion This exit interview study provides qualitative evidence to support the interpretation of the clinical trial findings for retatrutide in the treatment of obesity, with detailed descriptions from participants of positive experiences relating to weight loss, eating behaviors, physical aspects, emotions, and lifestyle
Human pharmacokinetic studies do not support that figure
Greater weight reduction may also require more careful monitoring, especially for gastrointestinal side effects, hydration, nutrition adequacy, gallbladder symptoms, medication interactions, and muscle preservation
Counterfeit sleeping pills containing nitazines have caused a rash of overdoses in prisons in Ireland